New drug combo tested to keep lung cancer from coming back
NCT ID NCT06267001
Summary
This study tested whether adding the experimental drug tiragolumab to the existing drug atezolizumab could better prevent lung cancer from returning in people who had already undergone surgery and chemotherapy. It involved 56 people with early-stage non-small cell lung cancer that had been completely removed. The trial was stopped early and focused only on checking the safety of the treatment combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji
Bakirkoy / Istanbul, 34147, Turkey (Türkiye)
-
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
-
Changzhou First People's Hospital
Changzhou, 213003, China
-
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, 60336-232, Brazil
-
E-DA Hospital
Kaohsiung City, 824, Taiwan
-
Guangdong General Hospital
Guangzhou, 510080, China
-
Hiroshima University Hospital
Hiroshima, 734-8551, Japan
-
Hospital A. C. Camargo
São Paulo, São Paulo, 01509-010, Brazil
-
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
Hospital de Cancer de Barretos
Barretos, São Paulo, 14784-400, Brazil
-
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, 99010-260, Brazil
-
Instytut Gruzlicy I Chorob Pluc
Warsaw, 01-138, Poland
-
Kindai University Hospital
Osaka, 589-8511, Japan
-
Korea University Guro Hospital
Seoul, 08308, South Korea
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
Liaoning Provincial Cancer Hospital
Shengyang, 110042, China
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, 210008, China
-
National Taiwan University Cancer Center
Zhongzheng Dist., 106, Taiwan
-
Ningbo No.2 Hospital
Ningbo, DUMMY_VALUE, China
-
Nucleo de Oncologia da Bahia - NOB
Salvador, Bahia, Estado de Bahia, 40170-380, Brazil
-
Ospedale P. Pederzoli Casa di cura Privata
Peschiera Del Garda (VR), Veneto, 37019, Italy
-
Pusan National University Hospital
Busan, 602-739, South Korea
-
Pusan National University Yangsan Hospital
Gyeongsangnam-do, 50612, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, 463-707, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Shandong Cancer Hospital
Jinan, 250117, China
-
St. Vincent's Hospital
Gyeonggi-do, 16247, South Korea
-
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, 510080, China
-
Tianjin Cancer Hospital
Tianjin, 300060, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430030, China
-
Vajira Hospital
Bangkok, 10300, Thailand
-
Yunnan Cancer Hospital
Kunming, 650118, China
-
Zhejiang Cancer Hospital
Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.